British Columbia Cancer Agency

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors

Not Applicable

Not yet recruiting

Conditions: Breast Cancer
Metastases

First Posted Date: 2025-04-22

Last Posted Date: 2025-04-24

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 40

Registration Number: NCT06937281

Locations: 🇨🇦
BC Cancer - Vancouver, Vancouver, British Columbia, Canada

DOTATATE PET for Meningioma Radiation Planning

Not Applicable

Not yet recruiting

Conditions: Meningioma

First Posted Date: 2025-04-22

Last Posted Date: 2025-04-22

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 36

Registration Number: NCT06937268

Locations: 🇨🇦
BC Cancer - Vancouver, Vancouver, British Columbia, Canada

Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers

Not Applicable

Not yet recruiting

Conditions: Oligoprogression
Oligometastatic Disease
OligoProgressive Metastatic Disease

First Posted Date: 2025-04-09

Last Posted Date: 2025-04-09

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 194

Registration Number: NCT06918951

Locations: 🇨🇦
BC Cancer - Surrey, Surrey, British Columbia, Canada

Phase II Single Vs Hypofractionated Irradiation for Timely Access to Partial Breast Radiotherapy

Not Applicable

Not yet recruiting

Conditions: Breast Cancer Early Stage Breast Cancer (Stage 1-3)

First Posted Date: 2025-03-20

Last Posted Date: 2025-03-20

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 60

Registration Number: NCT06885671

Time Restricted Eating in Haematological Malignancies

Phase 2

Not yet recruiting

Conditions: Cancer
Chronic Lymphocytic Leukemia

First Posted Date: 2025-03-06

Last Posted Date: 2025-03-06

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 75

Registration Number: NCT06862323

Locations: 🇨🇦
BC Cancer, Victoria, British Columbia, Canada

Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer

Phase 2

Not yet recruiting

Conditions: Prostate CA

First Posted Date: 2025-02-19

Last Posted Date: 2025-02-19

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 100

Registration Number: NCT06835725

Locations: 🇨🇦
BC Cancer Radiation Oncology, Victoria, British Columbia, Canada

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

Phase 2

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Sacituzumab Govitecan

First Posted Date: 2024-10-30

Last Posted Date: 2024-10-30

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 20

Registration Number: NCT06665178

Locations: 🇨🇦
BC Cancer - Vancouver Center, Vancouver, British Columbia, Canada

NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study

Phase 2

Not yet recruiting

Conditions: Ovarian Cancer Stage IV

Interventions: Drug: Olaparib
Drug: Bevacizumab
Drug: Durvalumab

First Posted Date: 2024-10-21

Last Posted Date: 2024-10-23

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 40

Registration Number: NCT06650709

Improving Detection of Early Lung Cancer in a Diverse Population (IDEAL) Study

Not Applicable

Recruiting

Conditions: Lung Cancer
Pulmonary Nodule

Interventions: Diagnostic Test: Chest CT Scan

First Posted Date: 2024-10-04

Last Posted Date: 2024-10-04

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 3600

Registration Number: NCT06628102

Locations: 🇨🇦
BC Cancer Research, part of the Provincial Health Authority, Vancouver, British Columbia, Canada

Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment

Not Applicable

Not yet recruiting

Conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma
Locally Advanced Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Resectable Pancreatic Ductal Adenocarcinoma

Interventions: Genetic: Genetic testing
Procedure: Optional biopsy

First Posted Date: 2024-08-28

Last Posted Date: 2025-02-06

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 200

Registration Number: NCT06574620

Locations: 🇨🇦
BC Cancer, Vancouver, British Columbia, Canada

Home Terms & Conditions Privacy Policy